Kaïssa de Boer, MD is a board certified pulmonologist who specializes in the care of patients with interstitial lung disease. She completed her Internal Medicine and Pulmonary training at the University of Ottawa, Ottawa, Canada where her initial interest in caring for patients with fibrotic lung disease first developed. Subsequently she completed a fellowship in Interstitial Lung Disease at the University of California, San Francisco under the direction of Dr. Harold Collard. Dr. de Boer has a special interest in patients with connective tissue disease associated lung disease and those with drug induced pneumonitis. In addition she is actively involved in the ILD training and program development of Stanford's Pulmonary Allergy and Critical Care Fellows.

Academic Appointments

All Publications

  • Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax Guler, S. A., Hur, S. A., Stickland, M. K., Brun, P., Bovet, L., Holland, A. E., Bondarenko, J., Hambly, N., Wald, J., Makhdami, N., Kreuter, M., Gloeckl, R., Jarosch, I., Tan, B., Johannson, K. A., McBride, S. A., De Boer, K., Sandoz, J. S., Sun, K., Assayag, D., Bhatt, S. P., Morisset, J., Ferraro, V., Garvey, C., Camp, P. G., Ryerson, C. J. 2021


    BACKGROUND: The impact of pulmonary rehabilitation (PR) on survival in patients with fibrotic interstitial lung disease (ILD) is unknown. Given the challenges conducting a large randomised controlled trial, we aimed to determine whether improvement in 6-minute walk distance (6MWD) was associated with better survival.METHODS: This retrospective, international cohort study included patients with fibrotic ILD participating in either inpatient or outpatient PR at 12 sites in 5 countries. Multivariable models were used to estimate the association between change in 6MWD and time to death or lung transplantation accounting for clustering by centre and other confounders.RESULTS: 701 participants (445 men and 256 women) with fibrotic ILD were included. The mean±SD ages of the 196 inpatients and 505 outpatients were 70±11 and 69±12 years, respectively. Baseline/changes in 6MWD were 262±128/55±83 m for inpatients and 358±125/34±65 m for outpatients. Improvement in 6MWD during PR was associated with lower hazard rates for death or lung transplant on adjusted analysis for both inpatient (HR per 10 m 0.94, 95% CI 0.91 to 0.97, p<0.001) and outpatient PR (HR 0.97, 95% CI 0.95 to 1.00, p=0.042). Participation in ≥80% of planned outpatient PR sessions was associated with a 33% lower risk of death (95% CI 0.49% to 0.92%).CONCLUSIONS: Patients with fibrotic ILD who improved physical performance during PR had better survival compared with those who did not improve performance. Confirmation of these hypothesis-generating findings in a randomised controlled trial would be required to definitely change clinical practice, and would further support efforts to improve availability of PR for patients with fibrotic ILD.

    View details for DOI 10.1136/thoraxjnl-2021-217361

    View details for PubMedID 34462346

  • Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., de Boer, K., Manganas, H., Shapero, S., Fell, C. D., Ryerson, C. J., Kolb, M. 2020
  • The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Canadian respiratory journal Ageely, G., Souza, C., De Boer, K., Zahra, S., Gomes, M., Voduc, N. 2020; 2020: 9026171


    Accurate diagnosis of interstitial lung disease (ILD) is crucial for management and prognosis but can be challenging even for experienced clinicians. Expert multidisciplinary discussion (MDD) is considered the reference standard for ILD diagnosis; however, there remain concerns regarding lack of validation studies and relative limited information on the impact of MDD in real-life clinical practice. The goal of this study was to assess the effect of MDD in providing a specific ILD diagnosis, changing the diagnosis provided upon referral, and to determine how often and in which way MDD altered management. Material and Methods. Retrospective observational study in an ILD referral tertiary academic center. MDD diagnoses were categorized as specific, provisional, and unclassifiable ILD. Pre-MDD and MDD diagnoses were compared for change in diagnosis and concordance rates for specific diagnoses. Relevant change in management including initiation or change in pharmacological treatment, referral to surgical biopsy, and nonpharmacological management were recorded. Results. 126 cases were included (79M, 47F, 36-93 years, mean 70y). Specific MDD diagnosis was provided in 62% (78/126); 12% (15/126) had provisional diagnosis, and 21% (27/126) was unclassifiable. Overall agreement for specific pre-MDD and MDD diagnosis was 41% (52/126) and 80% for idiopathic pulmonary fibrosis (IPF) diagnosis. MDD altered diagnosis in 37% (47/126) and changed management in 39% (50/126). Amongst concordant diagnoses, management was altered in 46% (24/52). In summary, MDD provided a specific diagnosis discordant with pre-MDD diagnosis in a significant proportion of cases and was particularly valuable in the diagnosis of non-IPF ILD. MDD often altered management and had relevant impact on management even in cases with concordant pre-MDD diagnosis.

    View details for DOI 10.1155/2020/9026171

    View details for PubMedID 32879642